Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370889 | 0.96 | CYP2C8 (0.61) | CYP2C8KCNH2CYP3A4NR1I2CYP2C9 | |
| SCHEMBL1918883 | 0.94 | CYP2C8 (0.68) | CYP2C8KCNH2CYP3A4NR1I2 | |
| SCHEMBL2370074 | 0.90 | CYP2C8 (0.62) | CYP2C8KCNH2CYP3A4NR1I2CYP2C9 | |
| SCHEMBL2369508 | 0.89 | CYP2C8 (0.59) | CYP2C8KCNH2CYP3A4NR1I2CYP2C9 | |
| SCHEMBL2369921 | 0.89 | CYP2C8 (0.60) | CYP2C8KCNH2CYP3A4NR1I2CYP2C9 | |
| SCHEMBL19385809 | 0.89 | CYP2C8 (0.66) | CYP2C8KCNH2CYP3A4NR1I2 | |
| SCHEMBL2437439 | 0.89 | CYP2C8 (0.57) | CYP2C8KCNH2CYP3A4NR1I2 | |
| SCHEMBL2435953 | 0.89 | CYP2C8 (0.57) | CYP2C8KCNH2CYP3A4NR1I2 | |
| SCHEMBL2369863 | 0.87 | CYP2C8 (0.60) | CYP2C8KCNH2CYP3A4NR1I2CYP2C9 | |
| SCHEMBL19385792 | 0.87 | CYP2C8 (0.66) | CYP2C8KCNH2CYP3A4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |